Esperion Therapeutics, Inc. (NASDAQ:ESPR) to Post Q2 2024 Earnings of ($0.16) Per Share, HC Wainwright Forecasts

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities research analysts at HC Wainwright boosted their Q2 2024 EPS estimates for Esperion Therapeutics in a report released on Wednesday, May 8th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn ($0.16) per share for the quarter, up from their previous forecast of ($0.21). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ Q3 2024 earnings at ($0.07) EPS, Q4 2024 earnings at $0.12 EPS, FY2024 earnings at $0.17 EPS and FY2025 earnings at $1.18 EPS.

Several other equities research analysts also recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Esperion Therapeutics in a report on Tuesday, May 7th. StockNews.com raised shares of Esperion Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Esperion Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $9.33.

Esperion Therapeutics Stock Up 4.8 %

Shares of NASDAQ ESPR opened at $2.19 on Monday. The business has a 50-day moving average price of $2.29 and a 200 day moving average price of $2.10. The stock has a market cap of $414.92 million, a PE ratio of -2.21 and a beta of 0.89. Esperion Therapeutics has a 52-week low of $0.70 and a 52-week high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.03. The company had revenue of $32.25 million during the quarter, compared to analyst estimates of $26.84 million. During the same quarter in the prior year, the company earned ($0.76) EPS.

Hedge Funds Weigh In On Esperion Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ESPR. Private Portfolio Partners LLC acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at about $30,000. Herbst Group LLC purchased a new position in Esperion Therapeutics during the first quarter worth about $28,000. CVI Holdings LLC acquired a new stake in Esperion Therapeutics in the 1st quarter worth about $37,000. Simplicity Wealth LLC purchased a new stake in Esperion Therapeutics in the 1st quarter valued at about $44,000. Finally, PSI Advisors LLC increased its stake in shares of Esperion Therapeutics by 161.5% during the 4th quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock valued at $51,000 after acquiring an additional 10,500 shares during the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.